How long does it take for drug resistance to develop after taking Osimertinib/Tagressa

Osimertinib is a third-generation EGFR inhibitor mainly used to treat EGFR mutation-positive non-small cell lung cancer (NSCLC). It has strong specificity and can effectively inhibit the abnormal signaling pathways caused by EGFR gene mutations, thereby inhibiting the proliferation and metastasis of tumor cells. Compared with first- and second-generation EGFR inhibitors, osimertinib has significant efficacy against EGFR T790M resistance mutations, making it one of the standard drugs for the treatment of EGFR mutation-positive lung cancer. However, despite the excellent clinical efficacy of osimertinib, the emergence of drug resistance is still an inevitable problem.

Generally speaking, the time for the development of resistance to osimertinib varies among individual patients, but most patients usually develop resistance between 6 to 12 months after receiving osimertinib treatment. The occurrence of drug resistance is caused by tumor cells overcoming the inhibitory effect of drugs through various mechanisms during treatment. Regarding the resistance mechanism of osimertinib, studies have shown that the main reasons include the emergence of new EGFR mutations, MET gene amplification, PIK3CA mutations, BRAF mutations, and phenotypic transformation of tumor cells.

PIK3CA and BRAF gene mutations also play a role in the occurrence of osimertinib resistance. PIK3CA mutations activate the PI3K/Akt signaling pathway, which plays a crucial role in cell proliferation and survival, thereby helping tumor cells overcome the effects of EGFR inhibition. BRAF mutations may trigger abnormal activation of the MAPK signaling pathway, further promoting tumor growth and drug resistance.

In addition to the above-mentioned gene mutations, phenotypic transformation of tumor cells is also a common mechanism of resistance to osimertinib. Some tumors may undergo epithelial-to-mesenchymal transition (EMT), making tumor cells more aggressive and resistant to drugs. This shift may be caused by long-term treatment and changes in the tumor microenvironment, making it difficult for the drug to work effectively.

Reference materials:https://go.drugbank.com/drugs/DB09330